Virax Biolabs Group Ltd stock is traded at $1.20, with a volume of 10,978,266. It is up +13.21% in the last 24 hours and down -50.00% over the past month. Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Previous Close:
$1.06
Open:
$1.16
24h Volume:
10,978,266
Relative Volume:
9.78
Market Cap:
$1.61M
Revenue:
$12,400
Net Income/Loss:
-$5.03M
P/E Ratio:
-
EPS:
-$16.91
Net Cash Flow:
-$4.87M
1W Performance:
-9.09%
1M Performance:
-50.00%
6M Performance:
-60.56%
1Y Performance:
-90.62%
1-Day Range:
$0.00$0.00
1-Week Range:
$1.04$1.57
52-Week Range:
$1.04$21.75
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS